Tirzepatide Effects on Metabolism in Type 1 Diabetes
Tests tirzepatide against placebo in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
Key facts
- Where
- Sydney, AustraliaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06820281, who can take part
Where in Australia
- Victor Chang Cardiac Research InstituteSydney, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Victor Chang Cardiac Research Institute
- Trial code
- NCT06820281
- Record updated
- 16 September 2026
- Original description
This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 6 weeks of treatment with TZP or placebo.Read full original descriptionShow less
Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)
This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 6 weeks of treatment with TZP or placebo.
Inclusion: age 18-70 years; BMI ≥ 25 kg/m2; HbA1c ≤ 9.0%; insulin delivery using an automated insulin delivery system; at least 2 years since diagnosis of type 1 diabetes.
Exclusion: History of seizure disorder; History of weight loss surgery; Liver disease (known cirrhosis, LFTs > 3x upper limit of normal); Active malignancy; Coronary event or stroke in last 6 months; TZP or GLP-1 receptor agonist in last 3 months; metformin or sodium glucose co-transporter 2 (SGLT2) inhibitor in the last 6 weeks; systemic steroids, antipsychotics, in the last 6 weeks; eGFR <60 mL/min/1.73 m2; Hemoglobin level < 13.5 g/dL in men, < 12.0 g/dL in women; Hypoglycemic unawareness or severe hypoglycemia last 6 months; Pregnant, breastfeeding, planning pregnancy within 6 months, or not using adequate contraception; Active or untreated proliferative diabetic retinopathy.